# Developmental Therapeutics Program

## One Dose Mean Graph

| | | |
|---|---|---|
| **NSC:** 764859 / 1 | **Conc:** 1.00E-5 Molar | **Test Date:** May 07, 2012 |
| **Experiment ID:** 1205OS68 | | **Report Date:** Oct 10, 2012 |

| Panel/Cell Line | Growth Percent |
|---|---|
| Leukemia | |
| CCRF-CEM | 109.88 |
| HL-60(TB) | 104.51 |
| K-562 | 98.03 |
| MOLT-4 | 96.71 |
| RPMI-8226 | 103.88 |
| Non-Small Cell Lung Cancer | |
| A549/ATCC | 94.87 |
| HOP-62 | 104.33 |
| HOP-92 | 101.44 |
| NCI-H226 | 90.15 |
| NCI-H23 | 105.78 |
| NCI-H322M | 103.15 |
| NCI-H460 | 104.25 |
| NCI-H522 | 89.62 |
| Colon Cancer | |
| COLO 205 | 109.11 |
| HCC-2998 | 113.94 |
| HCT-116 | 106.26 |
| HCT-15 | 104.15 |
| HT29 | 104.94 |
| KM12 | 109.39 |
| SW-620 | 104.52 |
| CNS Cancer | |
| SF-268 | 109.02 |
| SF-295 | 99.93 |
| SF-539 | 98.93 |
| SNB-19 | 105.07 |
| SNB-75 | 88.07 |
| U251 | 94.89 |
| Melanoma | |
| LOX IMVI | 105.67 |
| MALME-3M | 115.97 |
| M14 | 106.30 |
| MDA-MB-435 | 99.04 |
| SK-MEL-2 | 112.53 |
| SK-MEL-28 | 106.86 |
| SK-MEL-5 | 96.22 |
| UACC-257 | 99.12 |
| UACC-62 | 99.52 |
| Ovarian Cancer | |
| IGROV1 | 99.15 |
| OVCAR-3 | 114.17 |
| OVCAR-4 | 103.52 |
| OVCAR-5 | 107.19 |
| OVCAR-8 | 100.45 |
| NCI/ADR-RES | 110.83 |
| SK-OV-3 | 107.76 |
| Renal Cancer | |
| 786-0 | 99.44 |
| A498 | 96.67 |
| ACHN | 110.51 |
| CAKI-1 | 93.84 |
| RXF 393 | 101.49 |
| SN12C | 100.83 |
| TK-10 | 109.76 |
| UO-31 | 89.37 |
| Prostate Cancer | |
| PC-3 | 96.09 |
| DU-145 | 110.35 |
| Breast Cancer | |
| MCF7 | 93.35 |
| MDA-MB-231/ATCC | 107.14 |
| HS 578T | 105.40 |
| BT-549 | 103.49 |
| T-47D | 105.46 |
| MDA-MB-468 | 109.98 |
| Mean | 102.97 |
| Delta | 14.90 |
| Range | 27.90 |

**Mean Growth Percent - Growth Percent**